Briganix 180 mg (Brigatinib) is a cutting-edge oral medication designed to treat ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in ALK-positive lung cancer. This medication is particularly effective for patients whose cancer has progressed…
Briganix 90 mg (Brigatinib) is an advanced oral medication specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in some forms of lung cancer. Briganix 90 mg is especially effective…
